BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 9808509)

  • 1. Intralesionally implanted cisplatin plus systemic carmustine for the treatment of brain tumor in rats.
    Kong Q; Kleinschmidt-DeMasters BK; Lillehei KO
    J Surg Oncol; 1998 Oct; 69(2):76-82. PubMed ID: 9808509
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of intralesionally administered cisplatin-impregnated biodegradable polymer for the treatment of 9L gliosarcoma in the rat.
    Lillehei KO; Kong Q; Withrow SJ; Kleinschmidt-DeMasters B
    Neurosurgery; 1996 Dec; 39(6):1191-7; discussion 1197-9. PubMed ID: 8938774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intralesionally implanted cisplatin cures primary brain tumor in rats.
    Kong Q; Kleinschmidt-Demasters BK; Lillehei KO
    J Surg Oncol; 1997 Apr; 64(4):268-73. PubMed ID: 9142181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Local immunotherapy with interleukin-2 delivered from biodegradable polymer microspheres combined with interstitial chemotherapy: a novel treatment for experimental malignant glioma.
    Rhines LD; Sampath P; DiMeco F; Lawson HC; Tyler BM; Hanes J; Olivi A; Brem H
    Neurosurgery; 2003 Apr; 52(4):872-9; discussion 879-80. PubMed ID: 12657184
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interstitial chemotherapy of experimental brain tumors: comparison of intratumoral injection versus polymeric controlled release.
    Buahin KG; Brem H
    J Neurooncol; 1995 Nov; 26(2):103-10. PubMed ID: 8787852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Local delivery of minocycline and systemic BCNU have synergistic activity in the treatment of intracranial glioma.
    Frazier JL; Wang PP; Case D; Tyler BM; Pradilla G; Weingart JD; Brem H
    J Neurooncol; 2003 Sep; 64(3):203-9. PubMed ID: 14558595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. O6-benzylguanine potentiates the antitumor effect of locally delivered carmustine against an intracranial rat glioma.
    Rhines LD; Sampath P; Dolan ME; Tyler BM; Brem H; Weingart J
    Cancer Res; 2000 Nov; 60(22):6307-10. PubMed ID: 11103789
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intracerebral chemotherapy in the 9L rat brain tumor model.
    Kimler BF; Liu C; Evans RG; Morantz RA
    J Neurooncol; 1992 Nov; 14(3):191-200. PubMed ID: 1281224
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interstitial chemotherapy of the 9L gliosarcoma: controlled release polymers for drug delivery in the brain.
    Tamargo RJ; Myseros JS; Epstein JI; Yang MB; Chasin M; Brem H
    Cancer Res; 1993 Jan; 53(2):329-33. PubMed ID: 8417826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased tumor cures using combined radiosurgery and BCNU in the treatment of 9l glioma in the rat brain.
    Khil MS; Kolozsvary A; Apple M; Kim JH
    Int J Radiat Oncol Biol Phys; 2000 May; 47(2):511-6. PubMed ID: 10802380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DTI-015 produces cures in T9 gliosarcoma.
    Pietronigro D; Drnovsky F; Cravioto H; Ransohoff J
    Neoplasia; 2003; 5(1):17-22. PubMed ID: 12659666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improvement in the standard treatment for experimental glioma by fusing antibody Fc domain to endostatin.
    Grossman R; Tyler B; Hwang L; Zadnik P; Lal B; Javaherian K; Brem H
    J Neurosurg; 2011 Dec; 115(6):1139-46. PubMed ID: 21923243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Local delivery of interleukin-2 and adriamycin is synergistic in the treatment of experimental malignant glioma.
    Hsu W; Lesniak MS; Tyler B; Brem H
    J Neurooncol; 2005 Sep; 74(2):135-40. PubMed ID: 16193383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of minocycline in the treatment of intracranial 9L glioma.
    Weingart JD; Sipos EP; Brem H
    J Neurosurg; 1995 Apr; 82(4):635-40. PubMed ID: 7897527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systemic BCNU enhances the efficacy of local delivery of a topoisomerase I inhibitor against malignant glioma.
    Storm PB; Renard VM; Moriarity JL; Tyler B; Wilentz RE; Brem H; Weingart JD
    Cancer Chemother Pharmacol; 2004 Oct; 54(4):361-7. PubMed ID: 15197484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of intracranial temozolomide with intracranial carmustine improves survival when compared with either treatment alone in a rodent glioma model.
    Recinos VR; Tyler BM; Bekelis K; Sunshine SB; Vellimana A; Li KW; Brem H
    Neurosurgery; 2010 Mar; 66(3):530-7; discussion 537. PubMed ID: 20173548
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimizing interstitial delivery of BCNU from controlled release polymers for the treatment of brain tumors.
    Sipos EP; Tyler B; Piantadosi S; Burger PC; Brem H
    Cancer Chemother Pharmacol; 1997; 39(5):383-9. PubMed ID: 9054951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhancement of cisplatin efficacy by thalidomide in a 9L rat gliosarcoma model.
    Murphy S; Davey RA; Gu XQ; Haywood MC; McCann LA; Mather LE; Boyle FM
    J Neurooncol; 2007 Nov; 85(2):181-9. PubMed ID: 17534579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Local delivery of the topoisomerase I inhibitor camptothecin sodium prolongs survival in the rat intracranial 9L gliosarcoma model.
    Weingart JD; Thompson RC; Tyler B; Colvin OM; Brem H
    Int J Cancer; 1995 Sep; 62(5):605-9. PubMed ID: 7665233
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Local delivery of mitoxantrone for the treatment of malignant brain tumors in rats.
    DiMeco F; Li KW; Tyler BM; Wolf AS; Brem H; Olivi A
    J Neurosurg; 2002 Nov; 97(5):1173-8. PubMed ID: 12450040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.